Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02317793 2000-09-06
- 1 -
I.AXATIVE COMPOSITION
Field of the Invention
The present invention relates to a laxative composition,
more particularly a laxative composition containing a
therapeutic amount of simethicone or dimethicone.
Background of the Invention
Laxative compositions are typically categorized by the
mechanism in which they work, such as bulk, saline, stool
softener, lubricant, or stimulant as per the U.S. Food and Drug
Administration's monograph, Laxatives, Martindale, page 1070;
or Goodman and Gilman page 914. Bulk laxatives contain
materials such as psyllium, cellulose, polycarbophil, bran,
karaya and malt soup extract. Saline laxatives, such as
magnesium, hydroxide, sulfate, phosphate, and citrate salts act
by drawing water into the intestines. Stool softeners include
docusate salts and mineral oils. Lubricant laxatives include
mineral oil, and certain digestible plant oils. Lubricants
coat the fecal contents, preventing excess absorption of water
in the colon. Stimulants include bisacodyl, cascara sagrada,
senna, aloe, castor oil and dehydrocholic acid. Stimulant
laxatives work to increase intestinal motility by either
increasing peristaltic activity as a result of local
irritation, or by selective stimulation of the nerves which
activate intestinal smooth muscle.
In addition to the above compounds, US Pat. No. 5,418,220
discloses simethicone as a treatment for constipation. In the
patent example, one teaspoon of a dimethicone suspension
(approximately 33% in glycerin stearate and water) resulted in
laxation in a 2 year old patient approximately two hours after
administration.
MCP-227
13
CA 02317793 2007-04-25
77276-41
- 2 -
While the above materials are effective laxative
materials, there is a continuing need to enhance the
performance of these materials by providing faster onset of
action and superior efficacy.
Summary of the Invention
The present invention provides an effective amount
of simethicone or dimethicone and a stimulant laxative,
preferably simethicone and bisacodyl. It has been
surprisingly found that the incorporation of simethicone
enhances the efficacy of stimulant laxatives.
In a second embodiment the present invention
provides a method for improved delivery of the stimulant
laxatives, including bisacodyl and senna throughout the
lower gastro-intestinal tract when it is incorporated with
an effective amount of simethicone.
Other embodiments of the present invention provide
methods for treating diabetic gastro-paresis and gastro-
esophageal reflex disorder.
According to one aspect of the present invention,
there is provided a composition comprising (a) bisacodyl and
(b) simethicone, wherein the simethicone is for enhancing
efficacy of the bisacodyl.
According to another aspect of the present
invention, there is provided a use of simethicone in
preparation of a pharmaceutical composition comprising
bisacodyl for enhancing the efficacy of the bisacodyl in
treating constipation; improving gastro-intestinal motility;
treating diabetic gastro-paresis; or treating gastro-
esophageal reflux disorder.
CA 02317793 2007-04-25
77276-41
- 2a -
According to still another aspect of the present
invention, there is provided a use of simethicone for
enhancing the efficacy of bisacodyl in treating
constipation; improving gastro-intestinal motility; treating
diabetic gastro-paresis; or treating gastro-esophageal
reflux disorder.
According to yet another aspect of the present
invention, there is provided simethicone for enhancing the
efficacy of bisacodyl in treating constipation; improving
gastro-intestinal motility; treating diabetic gastro-
paresis; or treating gastro-esophageal reflux disorder.
Detailed Description of the Invention
Dimethicone is a well known pharmaceutical material
consisting of linear siloxane polymers containing repeating
units of the formula {-(CHz)2Si0}n stabilized with
trimethylsiloxy end blocking units of the formula [(CH3) 3SiO-] .
Simethicone is the mixture of dimethicone and silicon dioxide.
For the purposes of this invention, the two materials may be
used interchangably. The level of simethicone or dimethicone
in the present invention is sufficient to enhance the effect
of a stimulant laxative agent such as bisacodyl. Generally
this level is from about 0.1 mg to about 500 mg, preferably
from about 1 to about 500 mg, and most preferably from about
20 mg
CA 02317793 2007-04-25
77276-41
- 3 -
to about 125 mg per dosage unit. A dosage unit can be one
tablet, capsule, or suppository, one teaspoonful of a liquid,
or one single portion of any other sutiable delivery form.
Laxative agents include bisacodyl, cascara sagrada, danthron,
senna, phenolphthalein, aloe, castor oil, ricinoleic acid, and
dehydrocholic acid and mixtures of these laxatives, of which
bisacodyl and senna are preferred. The level of laxative is
the amount necessary to provide the desired effect, which is
generally from about 1.0 mg to about 100mg. preferably from
about 1.0 mg to about 50 mg, and most preferably from about
1.0mg to about 15 mg per dose for bisacodyl, and generally from
about 1.0 mg to about 100 mg, preferably from about 1.0 mg to
about 75 mg, and most preferably from about 1.0 mg to about 60
milligrams per dose for senna.
The present invention can be delivered as a tablet, a
chewable tablet, a liquid drink, a suppository or other
pharmaceutically acceptable forms. Oral delivery forms are
preferred.
Commonly known pharmaceutically acceptable additives
for orally-administered drugs such as enteric polymers,
taste-masking polymers, binders, sweeteners, flavoring
agents, dispersants, buffering agents and the like may be
included in amounts that do not adversely affect the novel
properties of the formulation described and claimed herein.
Suitable enteric polymer systems include polymethacryaltes
TM
(e.g. EUDRAGTT L30D or S100, available from Rohm Company);
cellulose acetate phthalate; polyvinyl acetate phthalate,
hydroxypropyl methylcellulose phthalate. Suitable binders
include microcrystalline cellulose, calcium phosphates,
dextrates. Suitable dispersants include croscarmellose
sodium, methylcellulose, hydroxymethylcellulose,
hydroxypropylmethylcellulose, hydroxyethylcellulose and the
CA 02317793 2000-09-06
- 4 -
like. Suitable sweeteners include sugar, sorbitol,
saccharin, mannitol, glucose, aspartame, sucralose and the
like. Flavoring agents include peppermint, spearmint,
cinnamon, vanilla and the like. A more complete listing of
appropriate additives can be found in numerous publications
including Remington's Encylcopedia.
The present invention is surprising and unexpected in
that PCT EP95/00973 previously disclosed that simethicone is
effective in association or affinity to the surface structure
of the GI tract. The PCT patent application continues that due
to the increased adhesion properties of dimethicone the
residence time of an active ingredient in a region of the GI
tract can be substantially prolonged if dimethicone is used as
a transport or carrier system.
As used herein diabetic gastro-paresis is defined as the
dilation of the stomach with gastric retention seen in
diabetics, commonly seen in association with severe acidosis or
coma, Stedmans Medical Dictionary. Gastro-esophogeal reflux
disorder (GERD) is defined as the regurgitation of the
contents of the stomach into the esophagus, possibly into
the pharynx where they can be aspirated between the vocal
cords and down into the trachea; providing symptoms of
burning pain and acid taste result; pulmonary complications
of aspirations are dependent upon the amount content and
acidity of the aspirate. Id.
The following examples are provided to further illustrate
the claimed invention, but not limit the invention to the
examples provided below.
MCP-227
CA 02317793 2007-04-25
77276-41
- 5 -
Example 1
A study was performed to characterize and compare the
effects of bisacodyl, simethicone and combinations of
bisacodyl and simethicone on small bowel transit time.
Small intestinal transit time was studied as a surrogate for
laxation in the rat. Leng-Peschlow, E., "Effect of
Sennosides A+B and Bisacodyl on rat large intestine",
Pharmacology, vol. 38 (1989), 310-318 (1989). observed
increased fecal output over the range of 10-100mg/kg of
bisacodyl given orally, large intestinal transit was
significantly stimulated by 50 mg/kg bisacodyl given orally.
The prokinetic efficacy of bisacodyl in the small intestine
may differ from that observed in the large intestine by
Leng-Psechlow. For the small intestinal transit model a
sub-therapeutic dose of 25mg/kg bisacodyl was chosen.
Rats were dosed with a suspension of powdered charcoal
which served as a non-absorbable marker. The rats were also
dosed with bisacodyl USP 23 (ZetaPharm, Inc.) and simethicone
supplied as MYLICONTM drops and activated charcoal (Sigma
Chemical). Six treatments were compared a control; simethicone
15 mg/kg; bisacodyl 25 mg/kg; and bisacodyl 25 mg/kg and
simethicone at 5, 10 or 15 mg/kilogram.
Dosing preparations of charcoal suspension (10 weight
percent) were made freshly each day by adding dry powder, to 0.5
percent methylcellulose in water and stirring. Dosing
preparations were made each day by adding the appropriate
quantity of bisacodyl and / or simethicone drops to the
charcoal suspension. A11 treatments were administered orally,
using the dose volume of 10 milliliters per kilogram.
CA 02317793 2000-09-06
- 6 -
Sixty minutes after dosing, the rats were sacrificed and
small bowel transit rate was determined by identifying the
charcoal marker and measuring its distance from the pylorus.
Results reveal that small bowel motility was greater in
rats treated with bisacodyl and simethicone combinations than
in rats treated with either bisacodyl or simethicone alone.
The results are presented below.
Mean ~ Std. Error
Treat:nernt traveled of Mean $ Increase
Vehicle Control 79.9 2.1 --
Simethicone 15mg/kg 79.1 2.0 -1
Bisacodyl 25 mg/kg 80.7 2.0 1
Bisacodyl 25 mg/kg + 90.3 2.5 13
Simethicone 5 mg/kg
Bisacodyl 25 mg/kg + 97.0 1.7 21
Simethicone 10 mg/kg
Bisacodyl 25 mg/kg + 94.4 2.0 18
Simethicone 15 mg/kg
The results reveal that although small bowel transit was
not differentfrom control in rats treated with simethicone
alone or bisacodyl alone, small bowel transit definitely
increased in rats treated with the. combination. The observed
increases in small bowel transit were sizable (13 to 21 percent
increase compared to the control) and the result was also
statistically significant (p less than 0.05).
MCP-227
CA 02317793 2007-04-25
77276-41
- 7 -
Exa.mple 2
Preparation of Chewable Tablets Containing Bisacodyl and
Simethicone
PART A.
1) 700 gm of granular tricalcium phosphate (TritabTM, Rhone-
Poulenc, Shelton, Ct) is added to the mixing bowl of a
TM
Kitchen Aid mixer.
2) While mixing at low speed, over a period of 5 minutes add
200 gm of simethicone, USP.
3) Continue mixing at low speed for an additional 5 minutes.
4) Add 2.5 gm of silicon dioxide and mix an additional 5
minutes.
PART B.
Preparation of enteric coated bisacodyl particles.
1. Rotogranulation.
Combine 0.52 kg. of Bisacodyl, 0.24 kg. of Hydroxypropyl
Methylcellulose ( grade Methocel E5) and 3.24 kg. of
Lactose impalpable in a rotor granulator bowl. Rotor
granulate by spraying water (approx. 1.0 kg.) at a rotor
speed of 500 RPM. Dry the rotogranulated particles to a
product temperature of 30 -35 C after decreasing rotor
speed to 250 RPM.
2. Particle Coating.
Coat the particles produced in Step A in a Wurster
Coating apparatus. The polymer coating solution should
consist of the following; approximately 35% by weight aq.
dispersion of EudragitTM L30D containing approx. 2.5%
Triethyl citrate. Apply 10-40% by weight polymer to the
particles. Maintain product temperature at about 30-32 C
during the coating step. A further tastemasking coat is
then applied as follows. The polymer coating solution
CA 02317793 2007-04-25
77276-41
- 8 -
should consist of 10% by weight solution of cellulose
acetate 398-10, (39.8%acetyl content; 10 seconds
TM
viscosity) and hydroxypropylcellulose (Klucel EF) where
the ratio of CA to HPC is 70/30. The solvent used is an
80/20 mixture of acetone/methanol. Apply a 5-10% by
weight polymer coat to the particles. Maintain a product
temperature at about 40-42 C during coating.
PART C.
1) Blend 89 gm of the free flowing granular intermediate
from Part A. with 7.34g of coated bisacodyl, 98 gm of
Dextrates, 7.5 gm granular sorbitol, 0.6 gm peppermint
flavor, and 0.5 gm stearic acid.
2) Compress the blend using 5/8" FFBE tooling to a tablet
weight of 1287 mg
CA 02317793 2007-04-25
77276-41
- 9 -
Example 3
Preparation of Swallowable Film Coated Tablets Containing
Bisacodyl and Simethicone.
Qty
Ingredient (mg/tab)
PART I ~ concentrate
Dibasic calcium phosphate, NF, Anhydrous, granular 500
(DiTabT ")
Simethicone, USP 125
Tribasic calcium phosphate, NF, Anhydrous, Powder 25
Dibasic calcium phosphate, NF, Anhydrous, granular 90
Powder (Fujical.in'" SG)
PART II- Bisacodyl/Excipient/Binder system
Bisacodyl, USP 5
Microcrystalline cellulose, NF (MCC) 205
Croscarmellose sodium, NF 30
PART III-Lubricant
Magnesium Stearate, NF 4
PART VI- Enteric Coating Step
EudragitTM S100 140
PAR 2 1)
A concentrate comprised of granular anhydrous dibasic
calcium phosphates, and simethicone is prepared by adding
simethicone compound, USP to a moving bed of granular
dibasic calcium phosphate so that the simethicone is
distributed evenly and the granular calcium phosphate
particle size remains essentially unchanged. The bed is
kept in motion by low shear mixers such as fluid bed, Nauta,
PK without intensifier bar, pin mixer, or ribbon mixer. The
granulation may then be screened through a No. 20 US Std
screen (- 840 micron).
CA 02317793 2000-09-06
- 10 -
PART 2)
Bisacodyl is added with low shear blending until the active
ingredient is uniformly dispersed in the Simethicone blend.
Excipients including a disintegrant are then added with low
shear blending which imparts uniform distribution of the
active within a binding matrix of limited compositional
range.
PART 3)
The final addition step is to add a lubricant.
The blend is compressed into tablets using a rotary tablet
press.
PART 4)
Tablets are then enteric film coated in a coating pan with
an Eudragit S100 dispersion to a weight increase of
approximately 5-25%.
MCP-227
